Yarrow Bioscience raises $173M in public offering to fund thyroid pipeline
What's the deal? Yarrow BioscienceDealroom has a profile for this one. Try Dealroom → raised $172.5 million in a public offering that closed on September 14, 2026. The clinical-stage biotech sold 6,634,615 shares at $26.00 each, with underwriters exercising their full option for 865,384 additional shares.
What's the endgame? Yarrow is developing YB-101, an anti-thyroid stimulating hormone receptor antibody for Graves' disease and thyroid eye disease. It describes the candidate as a potential first-in-class therapy and is advancing a Phase 2a/2b program.
The numbers: Yarrow reported a net loss of $9.3 million for the six months ended June 30, 2026, with cash of $18.7 million at that date. Management said its liquidity would fund operations for at least 12 months — a runway the new offering extends considerably.
Why now? The company funds research and development rather than an established commercial product, so financing is central to its investment case. The transaction also increases the share count.
What could go wrong? The offering extends Yarrow's runway but does not remove development and execution risk. Its shares last traded at $22.52 on Nasdaq on September 30, 2026, below the $26.00 offering price, within a 52-week range of $16.00 to $46.95.
The signal: At $172.5 million, Yarrow's raise ranks in the 91st percentile of all-time post-IPO equity rounds in health, based on a sample of 6,289 deals. That places it among the larger clinical-stage financings in the sector, underscoring investor appetite for autoimmune thyroid programs despite ongoing losses.
Read more: ad-hoc-news.de
Image credit: Generated with Gemini
